Literature DB >> 26643677

Clinical Evaluation of the Safety and Feasibility of Whole Autologous Cord Blood Transplant as a Source of Stem and Progenitor Cells for Extremely Premature Neonates: Preliminary Report.

Jacek Rudnicki1, Miłosz Piotr Kawa, Maciej Kotowski, Barbara Michalczyk, Przemysław Ustianowski, Ryszard Czajka, Bogusław Machaliński.   

Abstract

OBJECTIVES: This is a preliminary, single-center, prospective study in the field of autologous cord blood transplant. We investigated the feasibility, safety, and tolerability of autologous whole cord blood transplant in extremely premature infants as a potential therapeutic modality to prevent developing complications related to prematurity.
MATERIALS AND METHODS: This preliminary prospective study (ClinicalTrials.gov identifier NCT02050971) included preterm infants born at less than 32 weeks of gestational age who developed anemia because of prematurity. Infants were assigned to 2 groups: (1) those receiving an autologous cord blood transfusion within 5 days postpartum (n = 5) and (2) those who obtained only an allogeneic red blood cell transfusion when necessary (n = 9; control group). Vital measurements were performed during and after transfusion, and peripheral blood pH, hematocrit, glucose, and calcium and potassium ion levels were measured over the next 4 days.
RESULTS: Oxygen saturation was significantly increased throughout the cord blood transfusion and in the subsequent 48 hours. No significant differences were found in vital measurements, such as arterial blood pressure (mean, systolic, and diastolic) or heart rate over the first 48 hours posttransfusion. Similarly, no significant differences were found in biochemical analyses of blood with the exception of pH level. We found initial pH level to be significantly augmented in the cord blood recipient group by the first day after transplant, which remained significantly higher for next 24 hours compared with that shown in the control group.
CONCLUSIONS: Collection, preparation, and short-term storage of unfrozen cord blood are feasible for clinical use. Our results showed general safety and tolerability of the procedure of whole autologous cord blood transplant in recruited preterm newborns. However, because our study group was small, these results need to be confirmed in further investigations with a larger patient cohort.

Entities:  

Mesh:

Year:  2015        PMID: 26643677

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  6 in total

1.  Safety and feasibility of umbilical cord blood collection from preterm neonates after delayed cord clamping for the use of improving preterm complications.

Authors:  Zhuxiao Ren; Fang Xu; Jianlan Wang; Zhicheng Zhong; Wei Wei; Jiying Wen; Qi Wang; Liu Guocheng; Jie Yang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Comparative Analysis of Global Gene Expression and Complement Components Levels in Umbilical Cord Blood from Preterm and Term Neonates: Implications for Significant Downregulation of Immune Response Pathways related to Prematurity.

Authors:  Dorota Gródecka-Szwajkiewicz; Zofia Ulańczyk; Edyta Zagrodnik; Karolina Łuczkowska; Dorota Rogińska; Miłosz P Kawa; Iwona Stecewicz; Krzysztof Safranow; Przemysław Ustianowski; Sławomir Szymański; Bogusław Machaliński
Journal:  Int J Med Sci       Date:  2020-07-11       Impact factor: 3.738

3.  Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT03053076].

Authors:  Zhuxiao Ren; Xu Fang; Qi Zhang; Y G Mai; X Y Tang; Q Q Wang; C H Lai; W H Mo; Y H Dai; Q Meng; Jing Wu; Z Z Ao; H Q Jiang; Yong Yang; L H Qu; C B Deng; Wei Wei; Yongsheng Li; Q I Wang; Jie Yang
Journal:  Front Pediatr       Date:  2020-04-02       Impact factor: 3.418

4.  Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications.

Authors:  Zhuxiao Ren; Fang Xu; Xiaoling Zhang; Chunyi Zhang; Jiayu Miao; Xin Xia; Mengmeng Kang; Wei Wei; Tianbao Ma; Qi Zhang; Lijuan Lu; Jiying Wen; Guocheng Liu; Kaiyan Liu; Qi Wang; Jie Yang
Journal:  Stem Cells Transl Med       Date:  2019-11-08       Impact factor: 6.940

Review 5.  Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis.

Authors:  Runzhen Zhao; Zhenlei Su; Jing Wu; Hong-Long Ji
Journal:  Oncotarget       Date:  2017-05-02

6.  Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study.

Authors:  Jie Yang; Zhuxiao Ren; Chunyi Zhang; Yunbei Rao; Junjuan Zhong; Zhu Wang; Zhipeng Liu; Wei Wei; Lijuang Lu; Jiying Wen; Guocheng Liu; Kaiyan Liu; Qi Wang
Journal:  Stem Cells Int       Date:  2018-08-15       Impact factor: 5.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.